Genetic
LY3884961
LY3884961 is a genetic therapy with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Active, not recruiting2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
recruiting133%
active_not_recruiting267%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_1
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
NCT05487599
active_not_recruitingphase_1
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
NCT04411654
active_not_recruitingphase_1
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
NCT04127578
Clinical Trials (3)
Showing 3 of 3 trials
NCT05487599Phase 1
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
NCT04411654Phase 1
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
NCT04127578Phase 1
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3